SIL modulates metabolic reprogramming by reducing triglyceride accumulation in the liver, ameliorates insulin resistance through the IRS-1/PI3K/Akt pathways, and provides cardioprotection by attenuating injury markers while inhibiting apoptotic signaling [27,28,29]. The gene discussed is AKT1; the disease is Insulin resistance.